Skip to main content
. 2020 Mar 14;12(3):763. doi: 10.3390/nu12030763

Figure 2.

Figure 2

Effects of L. lactis 11/19-B1 intake on the development of 1-fluoro-2, 4-dinitrobenzene (DNFB)-induced AD-like symptoms. (A) Schematic representation of the experiment. (B) The severity of AD-like skin lesions was evaluated at 24 h after the repeated application of DNFB on day 25. Images are from a single experiment and are representative of each group (n = 4). (C) Ear swelling at 1 and 6 h after the last DNFB application (day 27) is shown. (D) The blood samples were collected at 6 h after the last DNFB application, and plasma total IgE was measured by ELISA. Results are expressed as the means ± standard deviation (SD) of four determinations for each group (n = 4). * p < 0.05, ** p < 0.01, *** p < 0.001 by Mann–Whitney U test. 1-fluoro-2, 4-dinitrobenzene (DNFB), vehicle group (Vehicle), atopic group (Atopic), lactic acid bacteria (LAB), L. lactis JCM20101 (JCM20101), L. lactis 11/19-B1 (11/19-B1), L. bulgaricus (L.B), B. lactis (B.L), L. acidophilus (L.A), S. thermophilus (S.T).